Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

ZAMBON SPA

Home Clinical Trial Sponsors and OrganizationsZAMBON SPA

ZAMBON SPA

ACTIVE

VIA LILLO DEL DUCA 10, Bresso, Milano, Italywww.zambon.comSubsidiary

Part of ZAMBON COMPANY SPA

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

44

20 active

Approvals

4

Total approvals

Agencies

2

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 1

26

59.1%

Phase 3

10

22.7%

Phase 2

3

6.8%

Not Applicable

1

2.3%

Phase 4

1

2.3%

Trial Status Distribution

Active, not recruiting

20

45.5%

Completed

20

45.5%

Recruiting

1

2.3%

Terminated

2

4.5%

Withdrawn

1

2.3%

Clinical Trials

Trials sponsored by this organization (44)

A Retrospective Chart Review Study of Patients With CLAD-BOS Post Lung Transplantation

Jun 2024284 participants

Clinical research study to investigate efficacy and safety of Liposomal Cyclosporine A (L-CsA) in patients with Bronchiolitis Obliterans Syndrome after Single or Double Lung Transplantation.

Dec 2022220 participants

Clinical research study to investigate efficacy and safety of Liposomal Cyclosporine A (L-CsA) in patients with Bronchiolitis Obliterans Syndrome after Single or Double Lung Transplantation.

Active, not recruiting

Nov 2021220 participants

Clinical research study to investigate efficacy and safety of Liposomal Cyclosporine A (L-CsA) in patients with Bronchiolitis obliterans syndrome after double lung transplantation.

Active, not recruiting

Sep 2021170 participants

A Single and Multiple Dose Study to Assess How the Drug Enters, Moves Through and Exits the Body, Safety and Tolerability of Safinamide in Healthy Adult Chinese Volunteers

Jun 202124 participants

A double-blind, placebo-controlled, multi-centre, clinical trial to investigate the efficacy and safety of 12 months of therapy with inhaled colistimethate sodium in the treatment of subjects with non-cystic fibrosis bronchiectasis chronically infected with Pseudomonas aeruginosa (P. aeruginosa)

Active, not recruiting

Jan 2021420 participants

A study evaluating the safety and efficacy of safinamide for patients with Multiple System Atrophy

Active, not recruiting

Jan 202148 participants

A double-blind, placebo controlled, multicentre, clinical trial to investigate the efficacy and safety of 12 months of therapy with inhaled colistimethate sodium in the treatment of subjects with non-cystic fibrosis bronchiectasischronically infected with Pseudomonas aeruginosa (P. aeruginosa)

Active, not recruiting

Oct 2020420 participants

Page 1 of 6

Approvals

Approvals by Agency

EMA

European Medicines Agency

2

Approvals

SFDA

Saudi Food and Drug Authority

2

Approvals

Recent Approvals

News

NCFB Pipeline Shows Promise with Over 15 Companies Developing New Therapies

• The non-cystic fibrosis bronchiectasis (NCFB) market is experiencing growth due to rising prevalence and increased awareness, leading to early diagnosis and treatment. • Over 15 companies are actively developing more than 15 NCFB drugs, aiming to improve the treatment landscape for this chronic lung condition. • Key players like Insmed, AstraZeneca, and Verona Pharma are advancing promising therapies such as brensocatib, benralizumab and ensifentrine through clinical trials. • Recent clinical trial milestones, including Phase III results for brensocatib and Phase II enrollment for AP-PA02, signal progress in addressing unmet needs in NCFB treatment.

On this page

Overview
Clinical Trials44
Approvals4
News1

Back to Organizations